atherosclerosis l-carnitine γ–Butyrobetaine is a pro-atherogenic intermediate in gut microbial metabolism of to TMAO γ-Butyrobetaine Is a Proatherogenic Intermediate

Subsequently, the cells were treated with BPTES (3 M, a glutaminase inhibitor that blocks the glutamine oxidation pathway), etomoxir (4 M, a CPT1A inhibitor, which is crucial for the transport of long-chain FAs from cytosol into mitochondria for oxidation), or UK5099 (2 M, an inhibitor of the glucose oxidation pathway that blocks the mitochondrial pyruvate carrier) successively, and oxygen consumption rate (OCR) was measured prior to and after the addition of each inhibitor

Liu et al., 2018)

The evidence base is expanding steadily: a 2024 review in the International Journal of Molecular Sciences as well as a 2025 systematic review in the Journal of Cosmetic Dermatology both reported consistent improvements in fine lines, tone and elasticity, with minimal and short lived side-effects

A recent study of discharge location and mortality after an intensive care unit stay for individuals living with Alzheimer's or other dementias found that patients with Alzheimer's had 1.5 times the odds of death in the same calendar month and 1.95 times the odds of death within one year of discharge compared to patients without the disease